Respond to new medical reform and build the core competitiveness of pharmaceutical companies.doc

 PAGE \* MERGEFORMAT 6 Respond to new medical reform and build the core competitiveness of pharmaceutical companies First, we analyze 20 years history of China’s medical reform, in this process, we may be able to find a strategy to deal with new medical reform, medical reform and thus take advantage of new opportunities to build the enterprise’s core competitiveness. The first phase of the 1980s, the landmark approach: policy does not give money only to The second phase of the practice of the 1990s, a landmark: Big controversy, naming surgery, special care, special wards and other new things like a sprung 2000 marked the third phase approach: property rights reform in horn, determined to implement the principles of Chinese medicine a number of sub-industries 2005 marked the fourth phase approach: a sudden variation of the Ministry of Health said the medical reform ‘market-oriented direction of the non-medical reform’ Phase V in 2006 a landmark approach: health reform goodbye to the dawn of health reform is scheduled to keynote the Government will bear the basic care. We can see from the policy is not only to give money to the market-oriented reform of non-medical direction, then the government will undertake basic health care, this process is a discontinuous process, illustrates the policy-making departments of hesitation and the direction of China’s medical reform impossible to grasp. Finally, that release no, letting go is not OK, it still holds partly concealed, that the Government will undertake basic medical care, so a lot of things seemingly unified purchase and marketing again appeared, such as tender, uniform distribution, the state money, then the Pharmaceutical marketing way that it must be the gateway to join the relevant government departments, and we call this half-turn. Over the years the precipitation of the pharmaceutical industry and the new medical reform impetus, another large-scale foreign capital to enter the pharmaceutical industry